Area of research
Immunology and Allergy · Surgery
Research interest
Research focused on Oral immunotherapy and Immunology, with related work in Allergy, Peanut allergy, Placebo. Notable publications include 'Oral Immunotherapy for Treatment of Egg Allergy in Children', 'The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease', and 'Omalizumab for the Treatment of Multiple Food Allergies'.
Interferon-γ Signaling in Eosinophilic Esophagitis Affects Epithelial Barrier Function and Programmed Cell Death
Treatment of Multi-Food Allergy with Omalizumab Compared to Omalizumab-Facilitated Multi-Allergen OIT
Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergies
Omalizumab for the Treatment of Multiple Food Allergies
Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy
The use and implementation of omalizumab as food allergy treatment: Consensus-based guidance and Work Group Report of the Adverse Reactions to Foods Committee of the American Academy of Allergy, Asthma & Immunology
Varying Doses of Epicutaneous Immunotherapy With Viaskin Milk vs Placebo in Children With Cow’s Milk Allergy
Interferon-γ signaling in eosinophilic esophagitis has implications for epithelial barrier function and programmed cell death
Immunotherapy-induced neutralizing antibodies disrupt allergen binding and sustain allergen tolerance in peanut allergy
Will Oral Food Challenges Still Be Part of Allergy Care in 10 Years’ Time?
The SunBEAm birth cohort: Protocol design
Updating the CoFAR Grading Scale for Systemic Allergic Reactions in Food Allergy
Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)
Longitudinal disease-associated gut microbiome differences in infants with food protein-induced allergic proctocolitis
Revealing the heterogeneity of CD4+ T cells through single-cell transcriptomics
Clonally expanded, GPR15-expressing pathogenic effector T <sub>H</sub> 2 cells are associated with eosinophilic esophagitis
Peanut oral immunotherapy differentially suppresses clonally distinct subsets of T helper cells
Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results
Safety of peanut (Arachis hypogaea) allergen powder-dnfp in children and teenagers with peanut allergy: Pooled summary of phase 3 and extension trials
Peanut oral immunotherapy differentially suppresses clonally distinct subsets of T helper cells
Sialylation of immunoglobulin E is a determinant of allergic pathogenicity
Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results
Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On Study
Consensus report from the Food Allergy Research & Education (FARE) 2019 Oral Immunotherapy for Food Allergy Summit
Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy
TCR sequencing paired with massively parallel 3′ RNA-seq reveals clonotypic T cell signatures
Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy
Expansion of the CD4+ effector T-cell repertoire characterizes peanut-allergic patients with heightened clinical sensitivity
Deriving individual threshold doses from clinical food challenge data for population risk assessment of food allergens
Current and Future Treatment of Peanut Allergy